All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

1,268

Reset

1,268 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • XNW28012Phase 32 trials

    Evopoint Biosciences Inc. · Pancreatic Cancer, Advanced Solid Tumors, Pancreatic Carcinoma

  • XZP-3287Phase 32 trials

    Xuanzhu Biopharmaceutical Co., Ltd. · Advanced Breast Cancer

  • ZN-A-1041ZN-A-1041 Enteric, RO7771950Phase 32 trials

    Roche (Genentech) · HER2-positive Breast Cancer, Advanced Solid Tumors

  • ABBV-1480Phase 31 trial

    AbbVie · Non-Small Cell Lung Cancer

  • AcasunlimabGEN1046, DuoBody-PD-L1×4-1BBPhase 31 trial

    Genmab · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

  • adebelizumabPhase 31 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced or Metastatic Non-small Cell Lung Cancer

  • AK105Phase 31 trial

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)

  • Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · Locally Advanced Pancreatic Cancer

  • Alflutinib MesylatePhase 31 trial

    Allist Pharmaceuticals, Inc. · Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

  • arboplatinPhase 31 trial

    Hansoh BioMedical R&D Company · Platinum-sensitive Recurrent Ovarian Cancer

  • ASP2138Phase 31 trial

    Astellas · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma

  • ASTX030cedazuridine + azacitidinePhase 31 trial

    Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm

  • SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma

  • Atigotatug+NivolumabBMS-986489Phase 31 trial

    Bristol Myers Squibb · Extensive-Stage Small Cell Lung Cancer

  • BecavizumabPhase 31 trial

    Roche (Genentech) · Hepatocellular Carcinoma

  • BemarituzumabPhase 31 trial

    Amgen · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

  • BGB-43395Phase 31 trial

    BeOne Medicines (BeiGene) · HR+/HER2- Breast Cancer

  • BMS-986365Phase 31 trial

    Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer

  • BNT113Phase 31 trial

    BioNTech SE · Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

  • Buparlisib & PaclitaxelAN2025Phase 31 trial

    Adlai Nortye Biopharma Co., Ltd. · Head and Neck Cancer

  • Jiangsu HengRui Medicine Co., Ltd. · Cervical Cancer

  • D07001-SoftgelPhase 31 trial

    InnoPharmax Inc. · Biliary Tract Cancer (BTC)

  • DalpciclibPhase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · Breast Cancer

  • DalpiciclibPhase 31 trial

    Risen (Suzhou) Pharma Tech Co., Ltd. · Breast Cancer

  • DeutenzalutamidePhase 31 trial

    AstraZeneca · Metastatic Castration-resistant Prostate Cancer

  • Amgen · Melanoma

  • F520Phase 31 trial

    Shandong New Time Pharmaceutical Co., LTD · Cancer of Unknown Primary Site

  • Amgen · Melanoma

  • FDA018-ADCPhase 31 trial

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer

  • FHND9041Phase 31 trial

    Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Non Small Cell Lung Cancer

  • FiclatuzumabAV-299Phase 31 trial

    AVEO Pharmaceuticals, Inc. · Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

  • Fixed of PertuzumabPhase 31 trial

    Roche (Genentech) · Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer

  • FuzuloparibPhase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • GB491Phase 31 trial

    Genor Biopharma Co., Ltd. · Breast Cancer

  • GLSI-100Phase 31 trial

    Greenwich LifeSciences, Inc. · Breast Cancer

  • GQ1005Phase 31 trial

    GeneQuantum Healthcare (Suzhou) Co., Ltd. · HER2-positive Breast Cancer

  • Hemay022Phase 31 trial

    Tianjin Hemay Pharmaceutical Co., Ltd · Breast Cancer

  • HLX11Phase 31 trial

    Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer

  • HLX13Phase 31 trial

    Shanghai Henlius Biotech · Hepatocellular Carcinoma (HCC)

  • HLX17Phase 31 trial

    Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer

  • HR070803Phase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · Colorectal Cancer

  • HR20013Phase 31 trial

    Fujian Shengdi Pharmaceutical Co., Ltd. · Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

  • HRS-4357Phase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

  • HS-10370Phase 31 trial

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Carcinoma, Non-Small-Cell Lung

  • HS-20117PM1080Phase 31 trial

    Hansoh BioMedical R&D Company · Non-Squamous Non-Small Cell Lung Cancer

  • HS627Phase 31 trial

    BioRay Pharmaceutical Co., Ltd. · Breast Cancer

  • HX22Phase 31 trial

    Shanghai Henlius Biotech · HER2 + Breast Cancer

  • IAH0968Phase 31 trial

    SUNHO(China)BioPharmaceutical CO., Ltd. · Stomach Neoplasms, Solid Tumor

  • IcotinibPhase 31 trial

    Betta Pharmaceuticals Co., Ltd. · Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy

  • IDRX-42velzatinib - subject to USAN approvalPhase 31 trial

    GSK · Gastrointestinal Neoplasms

NewerPage 7 of 26Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.